Department of Medicine, Far Eastern Memorial Hospital, New Taipei City 220, Taiwan.
J Crit Care. 2013 Aug;28(4):532.e1-10. doi: 10.1016/j.jcrc.2012.11.021. Epub 2013 Mar 19.
Limited data on the outcomes of adults with active sepsis undergoing extracorporeal membrane oxygenation (ECMO) exist.
We analyzed our prospective database for adults undergoing their first ECMO from 2001 to 2009. Patients with preexisting sepsis had newly emerging or uncontrolled infections precipitating refractory respiratory and/or circulatory failure within 7 days preceding ECMO. Propensity score matching was performed to equalize potential prognostic factors between patients with and patients without sepsis.
Of the 514 adults receiving their first ECMO, 108 with preexisting sepsis were matched with 108 without sepsis by propensity score. Overall survival to discharge did not differ between those with (28.7%) and those without sepsis (37.0%; P = .192). When venovenous ECMO and venoarterial ECMO were considered separately, survival tended to be worse for septic patients on venoarterial ECMO (24.4%) compared with nonseptic adults on venoarterial ECMO (34.9%; P = .147). After adjustments for age, stroke, acute myocarditis, inter-extracorporeal cardiopulmonary resuscitation, and post-ECMO renal and neurologic deficits by multivariate analysis, the increased risk of mortality persisted for septic adults receiving venoarterial ECMO (hazard ratio, 2.54; 95% confidence intervals, 1.75-3.70; P < .01). Patients on venovenous ECMO had similar outcomes regardless of preexisting sepsis.
Preexisting sepsis is not a contraindication for ECMO. However, venoarterial ECMO should be used with caution, given active sepsis.
关于接受体外膜氧合(ECMO)治疗的成人脓毒症患者结局的数据有限。
我们分析了 2001 年至 2009 年期间接受首次 ECMO 的成人的前瞻性数据库。有基础脓毒症的患者在接受 ECMO 前 7 天内出现新出现或未得到控制的感染,导致难治性呼吸和/或循环衰竭。通过倾向评分匹配来平衡脓毒症患者和非脓毒症患者之间的潜在预后因素。
在接受首次 ECMO 的 514 例成人中,有 108 例有基础脓毒症的患者通过倾向评分与 108 例无脓毒症的患者相匹配。出院时的总体生存率在有脓毒症的患者(28.7%)和无脓毒症的患者(37.0%)之间没有差异(P =.192)。当分别考虑静脉-静脉 ECMO 和静脉-动脉 ECMO 时,与静脉-动脉 ECMO 上的非脓毒症成人相比,静脉-动脉 ECMO 上的脓毒症患者的生存率倾向于更差(24.4%比 34.9%;P =.147)。通过多变量分析调整年龄、中风、急性心肌炎、体外心肺复苏期间、以及 ECMO 后肾和神经功能缺陷后,接受静脉-动脉 ECMO 的脓毒症成人的死亡率增加的风险仍然存在(风险比,2.54;95%置信区间,1.75-3.70;P <.01)。无论是否存在基础脓毒症,接受静脉-静脉 ECMO 的患者的结局相似。
有基础脓毒症不是 ECMO 的禁忌证。然而,鉴于存在活跃的脓毒症,应谨慎使用静脉-动脉 ECMO。